Advanced search
Publication Cover
Substance Use & Misuse Volume 51, 2016 - Issue 9
Submit an article Journal homepage
498
Views
109
CrossRef citations to date
0
Altmetric
Original Articles

Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs

Alice K. AsherSchool of Nursing, University of California, San Francisco, San Francisco, California, USA;Institute for Global Health, University of California, San Francisco, San Francisco, California, USACorrespondence[email protected]
View further author information
,
Carmen J. PortilloSchool of Nursing, University of California, San Francisco, San Francisco, California, USAView further author information
,
Bruce A. CooperSchool of Nursing, University of California, San Francisco, San Francisco, California, USAView further author information
,
Carol Dawson-RoseSchool of Nursing, University of California, San Francisco, San Francisco, California, USAView further author information
,
David VlahovSchool of Nursing, University of California, San Francisco, San Francisco, California, USAView further author information
&
Kimberly A. PageBiostatistics & Preventive Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USAView further author information
Pages 1218-1223 | Published online: 24 May 2016

References

  • Aghemo, A., & De Francesco, R. (2013). New horizons in Hepatitis C antiviral therapy with direct-acting antivirals. Hepatology, 58, 428–438.
  • Asher, A., Lum, P. J., & Page, K. (2012). Assessing candidacy for acute hepatitis C treatment among active young injection drug users: A case-series report. Journal of the Association of Nurses in AIDS Care, 23(1), 16–29.
  • Backmund, M., Meyer, K., & Edlin, B. R. (2004). Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clinical Infectious Diseases, 39(10), 1540–1543.
  • Batchelder, A. W., Peyser, D., Nahvi, S., Arnsten, J. H., & Litwin, A. H. (2015). “Hepatitis C treatment turned me around:” Psychological and behavioral transformation related to hepatitis C treatment. Drug & Alcohol Dependence, 153, 66–71.
  • Efron, B. (2000). The bootstrap and modern statistics. Journal of the American Statistical Association, 95(452), 1293–1296.
  • Erceg-Hurn, D. M., & Mirosevich, V. M. (2008). Modern robust statistical methods: An easy way to maximize the accuracy and power of your research. American Psychologist, 63(7), 591–601.
  • Ghany, M. G. (2015). The ongoing debate of who to treat for chronic hepatitis C virus. JAMA Internal Medicine, 175(2), 169–170.
  • Grady, B. P., Vanhommerig, J. W., Schinkel, J., Weegink, C. J., Bruisten, S. M., Lindenburg, C. E., & Prins, M. (2012). Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. European Journal of Gastroenterology & Hepatology, 24(11), 1302–1307.
  • Grebely, J., Knight, E., Ngai, T., Genoway, K. A., Raffa, J. D., Storms, M., … Conway, B. (2010). Reinfection with hepatitis C virus following sustained virological response in injection drug users. Journal of Gastroenterology and Hepatology, 25(7), 1281–1284.
  • Hagan, L. M., & Schinazi, R. F. (2013). Best strategies for global HCV eradication. Liver International, 33(Suppl 1), 68–79.
  • Hagan, L. M., Wolpe, P. R., & Schinazi, R. F. (2013). Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends in Microbiology, 21(12), 625–633.
  • Hellard, M., Doyle, J. S., Sacks-Davis, R., Thompson, A. J., & McBryde, E. (2014). Eradication of hepatitis C infection: The importance of targeting people who inject drugs. Hepatology, 59(2), 366–369.
  • Hellard, M., Sacks-Davis, R., & Gold, J. (2009). Hepatitis C treatment for injection drug users: A review of the available evidence. Clinical Infectious Diseases, 49(4), 561–573.
  • Kowdley, K. V., Lawitz, E., Crespo, I., Hassanein, T., Davis, M. N., DeMicco, M., … Jacobson, I. M. (2013). Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomised, multicentre phase 2 trial. Lancet, 381(9883), 2100–2107.
  • Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., … Gane, E. J. (2013). Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine, 368(20), 1878–1887.
  • Mehta, S. H., Genberg, B. L., Astemborski, J., Kavasery, R., Kirk, G. D., Vlahov, D., … Thomas, D. L. (2008). Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health, 33(3), 126–133.
  • Morrill, J. A., Shrestha, M., & Grant, R. W. (2005). Barriers to the treatment of hepatitis C. Patient, provider, and system factors. Journal of General Internal Medicine, 20(8), 754–758.
  • Myles, A., Mugford, G. J., Zhao, J., Krahn, M., & Wang, P. P. (2011). Physicians' attitudes and practice toward treating injection drug users with hepatitis C: Results from a national specialist survey in Canada. Canadian Journal of Gastroenterology, 25(3), 135–139.
  • Primrose Healthcare. (2015, July 8). The burden of hepatitis C virus disease in commercial and managed Medicaid populations. Retrieved from http://www.milliman.com/uploadedFiles/insight/2015/milliman-hcv-burden.pdf
  • StataCorp. (2013). Stata statistical software: Release 13. College Station, TX: Author.
  • Strathdee, S. A., Latka, M., Campbell, J., O'Driscoll, P. T., Golub, E. T., Kapadia, F., … Study to Reduce Intravenous Exposures Project. (2005). Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clinical Infectious Diseases, 40(Suppl 5), S304–S312.
  • Substance Abuse and Mental Health Services Administration. (2014). Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Author.
  • Wehrens, R., Putter, H., & Buydens, L. M. C. (2000). The bootstrap: A tutorial. Chemometrics and Intelligent Laboratory Systems, 54(1), 35–52.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.